{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:05:50Z","timestamp":1792058750821,"version":"4.4.0"},"reference-count":32,"publisher":"Massachusetts Medical Society","issue":"15","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"name":"Intellia Therapeutics","id":[{"id":"https:\/\/ror.org\/03b368668","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2026,10,15]]},"DOI":"10.1056\/nejmoa2600931","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:20:06Z","timestamp":1781331606000},"page":"1471-1482","source":"Crossref","is-referenced-by-count":10,"title":["Lonvoguran Ziclumeran \u2014 In Vivo CRISPR Gene Editing in Hereditary Angioedema"],"prefix":"10.1056","volume":"395","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9036-3723","authenticated-orcid":false,"given":"Danny M.","family":"Cohn","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmalal","family":"Gurugama","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary J.","family":"Longhurst","sequence":"additional","affiliation":[{"name":"Te Toka Tumai, Department of Immunology, Auckland City Hospital, Auckland, New Zealand"},{"name":"Department of Medicine, University of Auckland, Auckland, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren-P\u00fcrs\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Children and Adolescents, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Craig","sequence":"additional","affiliation":[{"name":"Penn State University Departments of Medicine, Pediatrics, OB\/GYN Maternal Fetal Medicine, and Biomedical Sciences, Hershey, PA"},{"name":"Health Allergy, Asthma, and Immunology, Department of Immunology, Vinmec Times City and VinUniversity, Hanoi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[{"name":"Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Allergy and Asthma Clinical Research, Walnut Creek, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[{"name":"Allergy and Asthma Research Associates Research Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[{"name":"Institute of Allergology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[{"name":"Division of Allergology and Clinical Immunology, Department of Medicine, Groote Schuur Hospital, University of Cape Town and Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[{"name":"University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Maag","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Golden","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal Y.","family":"Shah","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine R.","family":"Miller","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Xu","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Butler","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-1977","authenticated-orcid":false,"given":"David","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Leonard","sequence":"additional","affiliation":[{"name":"Intellia Therapeutics, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston"},{"name":"Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.08.046"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03382-6"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16773"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402478"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2026.47.260004"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14680"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1808012"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.015"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309149"},{"key":"e_1_3_5_12_2","doi-asserted-by":"crossref","unstructured":"Magerl M Gurugama P Katelaris CH et al. Long-term durability and safety of lonvoguran ziclumeran (lonvo-z NTLA-2002) 50 mg in patients with hereditary angiodema. J Allergy Clin Immunol 2026;157:Suppl:AB21-AB21. abstract (https:\/\/www.jacionline.org\/article\/S0091-6749(25)01250-3\/fulltext).","DOI":"10.1016\/j.jaci.2025.12.067"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.12900"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405734"},{"key":"e_1_3_5_15_2","doi-asserted-by":"crossref","unstructured":"Cohn DM Gurugama P Magerl M et al. Two-year durability\/safety of one-time lonvoguran ziclumeran (lonvo-z NTLA-2002) 50 mg in patients with hereditary angioedema. Ann Allergy Asthma Immunol 2025;135:Suppl 1:S9-S9. abstract (https:\/\/www.annallergy.org\/article\/S1081-1206(25)00461-2\/fulltext).","DOI":"10.1016\/j.anai.2025.08.036"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.10.003"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05843-9"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1408"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2022.05.001"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14805"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000735"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.190005"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000294"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03226-3"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.06.004"},{"key":"e_1_3_5_26_2","unstructured":"United States Securities and Exchange Commission. Form 8-K. January 9 2026 (https:\/\/ir.intelliatx.com\/node\/12426\/html)."},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2601283"},{"key":"e_1_3_5_28_2","unstructured":"Verve Therapeutics announces updates on its PCSK9 program. Press release of Verve Therapeutics Boston April 2 2024 (https:\/\/vervetx.gcs-web.com\/news-releases\/news-release-details\/verve-therapeutics-announces-updates-its-pcsk9-program)."},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03543-z"},{"key":"e_1_3_5_30_2","unstructured":"Simon A. The potential for base editing to treat diseases impacting the lungs: ongoing data from the BEAM-302 clinical trial in alpha-1 antitrypsin deficiency (AATD). New York: American Thoracic Society May 2026 (https:\/\/beamtx.com\/wp-content\/uploads\/2026\/05\/Amy-Simon-Presentation_ATS-2026_Draft-3_18May26_updated.pdf)."},{"key":"e_1_3_5_31_2","unstructured":"Beam Therapeutics announces compelling updated clinical data from the ongoing phase 1\/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD) to support advancement to pivotal development. Press release of Beam Therapeutics Cambridge MA March 25 2026 (https:\/\/investors.beamtx.com\/news-releases\/news-release-details\/beam-therapeutics-announces-compelling-updated-clinical-data\/)."},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200065"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-026-04254-0"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2600931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:08:12Z","timestamp":1792012092000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2600931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":32,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,10,15]]}},"alternative-id":["10.1056\/NEJMoa2600931"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2600931","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}